- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01951118
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this clinical trial, the investigators will evaluate, treat and follow two broad samples of adult patients at New York State Psychiatric Institute/Columbia University Medical Center. Study 1 will include 70 patients with amnestic Mild Cognitive Impairment (MCI). Study 2 will include 100 patients with probable Alzheimer's Disease (AD). Recruitment will be from clinics and/or advertisements. In the protocol, all 170 patients will receive baseline memory and olfactory assessments and are treated with donepezil. Patients will be followed for a total of 1 year. During this time, patients will be monitored closely by the study physician and will receive memory and olfactory assessments at weeks 0, 8, 26, and 52. In addition, an olfactory challenge test will be done at baseline.
This project will be of value in the selection of patients with MCI and AD for treatment based on the evaluation of olfaction tests to predict response to donepezil. Since mild cognitive impairment is widespread and Alzheimer's disease represents a major public health problem, this study has considerable public purpose and significance.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study 1
Inclusion Criteria:
- Of either sex, age 55-95 years old
Patients who meet criteria for amnestic mild cognitive impairment by meeting all of the following:
(i) subjective memory complaints (ii) Wechsler Memory Scale-III Logical Memory combined Story A + B immediate recall score or combined Story A + B delayed recall score or Free and Cued Selective Reminding Test immediate recall or delayed recall score greater than 1.5 Standard Deviation (SD) below norms or Selective Reminding Test immediate recall or delayed recall score greater than 1.5 SD below norms iii) no functional impairment consistent with dementia
- Folstein Mini Mental State (MMSE) score ≥ 23 out of 30
- Clinical Dementia Rating (CDR) of 0.5 (questionable dementia)
- Availability of informant
- Retains capacity to consent
Exclusion Criteria:
- Medical contraindication to donepezil treatment or prior history of intolerability to donepezil treatment.
- Medications with anticholinergic effects that have been shown to adversely impact cognition will not be permitted. Benzodiazepines in lorazepam equivalents less than or equal to 2 mg daily and narcotics will also not be permitted.
- Meets criteria for dementia by Diagnostic and Statistical Manual IV (DSM-IV) or probable Alzheimer's disease by National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
- Meets Diagnostic and Statistical Manual IV Text Revision (DSM IV TR) criteria for: (i)schizophrenia, schizoaffective disorder, other psychosis, or bipolar I disorder (ii)alcohol or substance dependence or abuse (current or within past 6 months)
- Current untreated major depression or suicidality
- Parkinson's disease, Lewy body disease, multiple sclerosis, central nervous system infection, Huntington's disease, amyotrophic lateral sclerosis, other major neurological disorder.
- Mental Retardation
- Cystic Fibrosis
- Clinical stroke with residual neurological deficits. MRI findings of cerebrovascular disease (small infarcts, lacunes, periventricular disease) in the absence of clinical stroke with residual neurological deficits will not lead to exclusion.
- Patients receiving cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine will be excluded. Patients already receiving one of these medications at screening who undergo a 2-week washout before starting all study procedures will not be excluded.
- Acute, severe, unstable medical illness. For cancer, patients with active illness or metastases will be excluded, but past history of successfully treated cancer will not lead to exclusion.
- Exclusion criterion for olfaction: history of anosmia due to any cause (e.g. traumatic or congenital) verified by UPSIT score of <11 out of 40; head trauma with loss of consciousness; nasal sinus disease, current upper respiratory infection; severe allergies to odors; current smoker > 1 pack daily.
- Exclusion criteria for atropine nasal spray: presence of nasal deformity or disease that makes it difficult to administer the nasal spray reliably. A patient who cannot complete the atropine nasal spray procedure can still participate in the rest of the study.
Study 2
Inclusion Criteria:
- Of either sex, age 55-95 years old
- Diagnosis of probable Alzheimer's disease (NINCDS-ADRDA criteria) and the diagnosis of "Probable AD dementia: core clinical diagnosis with amnestic or nonamnestic initial presentation".
- Folstein Mini Mental State (MMSE) score 18-27 out of 30
- Availability of informant
- Retains capacity to consent
Exclusion Criteria:
- Medical contraindication to donepezil treatment or prior history of intolerability to donepezil treatment.
- Medications with anticholinergic effects that have been shown to adversely impact cognition will not be permitted. Benzodiazepines in lorazepam equivalents less than or equal to 2 mg daily and narcotics will also not be permitted.
- Meets DSM IV TR criteria for:(i)schizophrenia, schizoaffective disorder, other psychosis, or bipolar I disorder (ii)alcohol or substance dependence or abuse (current or within past 6 months)
- Current untreated major depression or suicidality
- Parkinson's disease, Lewy body disease, multiple sclerosis, central nervous system infection, Huntington's disease, amyotrophic lateral sclerosis, other major neurological disorder.
- Mental Retardation
- Cystic Fibrosis
- Clinical stroke with residual neurological deficits. MRI findings of cerebrovascular disease (small infarcts, lacunes, periventricular disease) in the absence of clinical stroke with residual neurological deficits will not lead to exclusion.
- Patients receiving cholinesterase inhibitors (donepezil, rivastigmine, galantamine) or memantine will be excluded. Patients already receiving one of these medications at screening who undergo a 2-week washout before starting all study procedures will not be excluded.
- Acute, severe, unstable medical illness. For cancer, patients with active illness or metastases will be excluded, but past history of successfully treated cancer will not lead to exclusion.
- Exclusion criterion for olfaction: history of anosmia due to any cause (e.g. traumatic or congenital) verified by UPSIT score of <11 out of 40; head trauma with loss of consciousness; nasal sinus disease, current upper respiratory infection; severe allergies to odors; current smoker > 1 pack daily.
- Exclusion criteria for atropine nasal spray: presence of nasal deformity or disease that makes it difficult to administer the nasal spray reliably. A patient who cannot complete the atropine nasal spray procedure can still participate in the rest of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Donepezil Treatment & Atropine Challenge
Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration.
Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
|
Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day.
The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol.
Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change Over Time in Selective Reminding Test (SRT) Scores
Time Frame: Week 0, Week 8, Week 26, Week 52
|
The Selective Reminding Test (SRT) is a 12-item test of verbal learning and memory.
To administer, the researcher will read aloud a list of 12 words.
The participant repeats each word aloud to ensure that the word was heard correctly.
Immediately following the reading of all 12 words, the participant is asked to recall as many words as possible within the one minute time limit.
The participant is then reminded of the words they did not say and asked to recall the list again.
This process is repeated for 6 trials.
The total immediate recall is the total number of words recalled by the participant from all 6 trials.
This is the number that is reported.
Lower scores indicate fewer words recalled and a poorer performance.
|
Week 0, Week 8, Week 26, Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog)
Time Frame: Week 0, Week 8, Week 26, Week 52
|
The modified Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) is a cognitive battery that assesses learning, memory, language production, language comprehension, constructional praxis, ideational praxis, and orientation.
The ADAS-Cog is not a timed test and the participant's score does not depend on how rapidly the test is completed.
The ADAS-Cog total score is based on the total number of errors made in the test by the participant.
Therefore, a lower total score indicates a higher cognitive performance.
The total score ranges from 0 to 95 and is determined by summing the errors from 12 subscales.
The total score, indicating number of errors made, is the number that is reported at each timeframe.
|
Week 0, Week 8, Week 26, Week 52
|
Clinician's Interview Based Impression (CIBIC-plus)
Time Frame: Week 8, Week 26, Week 52
|
The CIBIC-plus is a well-validated, reliable and widely used measure (range 1-7) of global improvement used in AD and MCI trials.
This is a measure of change based on clinician impression.
Higher values represent a worse outcome.
|
Week 8, Week 26, Week 52
|
Pfeffer Functional Activities Questionnaire (FAQ)
Time Frame: Week 0, Week 8, Week 26, Week 52
|
FAQ is a widely used 10-item instrument that takes 3 minutes to administer and focuses on instrumental, social and cognitive functioning.
The assessment is completed by a study informant - typically a caregiver able to report best on the patient's current ability.
The instrument assesses the patient's current ability, at the point of testing and through the past month, in these various domains.
The total score is described as the cumulative scores of each item, ranging from "0 - No help needed" to "3 - No, unable to do."
More impairment is indicated by higher scores.
The reported total score range is from 0 (no impairment score) to 30 (maximum impairment score).
|
Week 0, Week 8, Week 26, Week 52
|
Measurement of Everyday Cognition (Ecog)
Time Frame: Week 0, Week 8, Week 26, Week 52
|
This instrument has 40 items, takes 20 minutes to administer, and focuses on functional correlates of cognitive deficits.
This assessment asks the study informant to rate the participant's ability to perform certain tasks with the domains of Memory, Language, Visual-spatial and Perceptual Abilities, Executive Functioning: Planning, Executive Functioning: Organization, and Executive Functioning: Divided Attention.
The informant is asked to compare functioning from 10 years prior to the time of testing.
The Everyday Cognition measure uses the sum score of all of the subscales, and the items are reverse coded (i.e., 1= "Better or no change", 2="Questionable/occasionally worse", 3="Consistently a little worse", 4="Consistently much worse"), meaning that lower scores are better.
Reported total scores range from 39 (Better or no change) to 156 (Consistently much worse).
|
Week 0, Week 8, Week 26, Week 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mini-Mental State Examination - MMSE
Time Frame: Week 0, Week 26, Week 52
|
The Mini Mental State Examination (MMSE) is a widely used 30-item test of cognitive function that includes tests of orientation, attention, memory, language, and visual-spatial skills.
Values range from 0-30; a higher value represents a better outcome.
|
Week 0, Week 26, Week 52
|
Trail Making Test (Parts A and B)
Time Frame: Week 0, Week 52
|
Parts A and B are composed of 25 circles.
Patients are asked to scan the entire page and identify the next number or letter in a sequence.
|
Week 0, Week 52
|
Wechsler Adult Intelligence Scale (WAIS) -III Digit Symbol Subtest
Time Frame: Week 0, Week 52
|
The Wechsler Adult Intelligence Scale (WAIS) -III Digit Symbol Subtest is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page.
Values range from 0-93; a higher value represents a better outcome.
|
Week 0, Week 52
|
Controlled Word Association (CFL)
Time Frame: Week 0, Week 52
|
Week 0, Week 52
|
|
Boston Naming Test (BNT)
Time Frame: Week 0, Week 52
|
Week 0, Week 52
|
|
Wechsler Memory Scale (WMS)-R Digit Span
Time Frame: Week 0, Week 52.
|
Week 0, Week 52.
|
|
Treatment Emergent Symptom Scale (TESS)
Time Frame: Week 0, Week 8, Week 26, Week 52
|
The Treatment Emergent Symptom Scale (TESS) is widely used to evaluate somatic side effects.
For each item, a rating is made on a 3-point scale, with an additional rating on the likelihood that the medication caused the side effect.
Values range from 0-78; a higher value indicates a worse outcome.
|
Week 0, Week 8, Week 26, Week 52
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Alzheimer Disease
- Cognitive Dysfunction
- Cognition Disorders
- Neurocognitive Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Donepezil
Other Study ID Numbers
- 6655
- 1R01AG041795 (NIH)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Donepezil
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.Eisai LimitedCompleted
-
Corium, Inc.CompletedAlzheimer DiseaseUnited States
-
Samsung Medical CenterEisai Korea Inc.CompletedDementia | Alzheimer's DiseaseKorea, Republic of
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.CompletedMigraine HeadacheUnited States
-
The First Affiliated Hospital with Nanjing Medical...Unknown
-
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.Completed